Endocyte Inc. plans to offer its common stock in an underwritten registered public offering.
The company expects to grant underwriters a 30-day option to buy up to an additional 15% of the shares sold under the offering.
Endocyte plans to use net proceeds to help develop its pipeline products, and for working capital and general corporate purposes.
Jefferies LLC, Wells Fargo Securities LLC and Deutsche Bank Securities Inc. are acting as joint book-running managers for the proposed offering.
West Lafayette, Ind.-based Endocyte develops targeted therapies for the personalized treatment of cancer.
